Literature DB >> 33496324

Recurrence of mesothelioma after a macroscopic complete resection procedure: is a second radical surgery justified?

Hany Hasan Elsayed1, Aly Sherif Hassaballa2, Taha Aly Ahmed2, Hazem Youssef Sharkawy2.   

Abstract

A best evidence topic was written according to a structured protocol. The question addressed was: In patients with mesothelioma who develop a local recurrence after macroscopic complete resection (MCR) surgery, does performing a second radical surgery lead to improvement in survival? A total of 2076 papers were identified using the reported search, of which 3 represented the best evidence to answer the clinical question. The authors, date, journal, country, study type, population, outcomes and key results are tabulated. The 2 largest studies included 16 patients each who underwent a second surgery for radical resection of recurrence after MCR for mesothelioma. One study (with 16 chest wall resections) had no in-hospital mortality, whereas the other study showed 2/16 (12.5%) patients dying in the hospital, both of whom had a contralateral pleurectomy. One study correlated the median survival after the second surgery with the time to recurrence and epithelioid pathology. The other study showed better post-recurrence survival after a second surgery, with patients having a significantly longer median post-recurrence survival (16 months) compared with those who received other types of second-line therapy (9 months) and those who received no therapy at all (2 months) (P < 0.0005), although selection bias is a possibility. The last study included 8 patients who underwent a second surgery for radical intent after MCR for mesothelioma. The median time to recurrence was 29 months and the survival after second surgery was 14.5 months with no correlation to disease-free interval (expected due to the small number of patients). In patients presenting with recurrence of mesothelioma after an MCR procedure, radical surgery to resect the recurrent tumour could have a role in improvement of survival in selected patients. Positive prognostic factors include epithelioid pathology and a longer disease-free interval after the first procedure.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Mesothelioma; Recurrence; Second surgery

Mesh:

Year:  2021        PMID: 33496324      PMCID: PMC8691530          DOI: 10.1093/icvts/ivaa338

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  4 in total

1.  Towards evidence-based medicine in cardiothoracic surgery: best BETS.

Authors:  Joel Dunning; Brian Prendergast; Kevin Mackway-Jones
Journal:  Interact Cardiovasc Thorac Surg       Date:  2003-12

2.  Second surgery for recurrence of malignant pleural mesothelioma after extrapleural pneumonectomy.

Authors:  Leonardo Politi; Giuseppe Borzellino
Journal:  Ann Thorac Surg       Date:  2010-01       Impact factor: 4.330

3.  Clinical indications and results after chest wall resection for recurrent mesothelioma.

Authors:  Bryan M Burt; Syed O Ali; Marcelo C DaSilva; Beow Y Yeap; William G Richards; Elizabeth H Baldini; David J Sugarbaker
Journal:  J Thorac Cardiovasc Surg       Date:  2013-10-08       Impact factor: 5.209

4.  Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma.

Authors:  Arthur Kostron; Martina Friess; Ornella Crameri; Ilhan Inci; Didier Schneiter; Sven Hillinger; Rolf Stahel; Walter Weder; Isabelle Opitz
Journal:  Eur J Cardiothorac Surg       Date:  2015-11-20       Impact factor: 4.191

  4 in total
  1 in total

Review 1.  Surgical Management and Reconstruction of Diaphragm, Pericardium and Chest Wall in Mesothelioma Surgery: A Review.

Authors:  Pietro Bertoglio; Elena Garelli; Jury Brandolini; Kenji Kawamukai; Filippo Antonacci; Sara Ricciardi; Alessandro Cipolli; Barbara Bonfanti; Sergio Nicola Forti Parri; Niccolò Daddi; Giampiero Dolci; Piergiorgio Solli
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.